L
Liminatus Pharma, Inc. (LIMN)
NGM – Real Time Price. Currency in USD
0.19
-0.01 (-3.90%)
At close: Mar 27, 2026, 4:00 PM EDT
0.19
+0.00 (1.33%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
NGM – Real Time Price. Currency in USD
0.19
-0.01 (-3.90%)
At close: Mar 27, 2026, 4:00 PM EDT
0.19
+0.00 (1.33%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPα blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
| Name | Position |
|---|---|
| Dr. Beom Kyu Choi | Chief Technology Officer & Member of Scientific Advisory Board |
| Dr. Byong Chul Yoo Ph.D. | Chief Science Officer & Member of Scientific Advisory Board |
| Dr. Sang-jin Lee Ph.D. | Head of Research & Development and Member of Scientific Advisory Board |
| Mr. Chris Kim J.D., L.L.M. | CEO & Chairman |
| Mr. Scott Dam | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-04 | 8-K | tm267974d1_8k.htm |
| 2026-01-26 | 8-K | tm264095d1_8k.htm |
| 2025-11-25 | 8-K | tm2532232d1_8k.htm |
| 2025-11-14 | 10-Q | limn-20250930x10q.htm |
| 2025-10-06 | 10-Q | limn-20250630x10q.htm |
| 2025-08-25 | 8-K | tm2524293d1_8k.htm |
| 2025-08-15 | NT 10-Q | tm2516820d2_nt10q.htm |
| 2025-08-14 | 8-K | tm2523534d1_8k.htm |
| 2025-07-28 | S-1/A | limn-20250331xs1a.htm |
| 2025-07-25 | CORRESP | filename1.htm |